Nevro Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Kevin Thornal

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Kevin Thornal (49 yo)

less than a year

Permanencia

Mr. Kevin R. Thornal serves as President & Chief Executive Officer at Nevro Corp. since April 24, 2023 and serves as its Director since May 2023. He joined Nevro Corp. on April 24, 2023. He serves as Acti...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Roderick MacLeod	Senior VP & CFO	3.8yrs	US$2.74m	0.052% $ 240.6k
Kashif Rashid	Senior VP of Corporate Development & Chief Legal Officer	6.3yrs	US$3.24m	0.12% $ 536.5k
Kevin Thornal	President	less than a year	sin datos	sin datos
Richard Carter	Chief Accounting Officer	1.6yrs	sin datos	0.025% $ 116.2k
Christofer Christoforou	Senior Vice President of Technical Operations	1.3yrs	US$2.87m	sin datos
Geeta Kaveti	VP and Chief Compliance & Privacy Officer	1.3yrs	sin datos	sin datos
Meredith Vornholt	Vice President of Global Marketing	2.3yrs	sin datos	sin datos
Shana Ross	Senior VP & Chief Human Resources Officer	1.3yrs	sin datos	sin datos
David Caraway	Senior VP & Chief Medical Officer	10yrs	sin datos	sin datos
Donald Middlebrook	Senior Vice President of Clinical & Regulatory Affairs	1.3yrs	sin datos	sin datos
Greg Siller	Senior VP & Chief Commercial Officer	less than a year	sin datos	sin datos
Peter Socarras	VP, General Counsel & Corporate Secretary	no data	sin datos	sin datos

1.3yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: NVROEl equipo directivo de la empresa no se considera experimentado ( 1.1 años de permanencia media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Thornal	President	less than a year	sin datos	sin datos
Frank Fischer	Independent Director	11.5yrs	US$247.00k	0.14% $ 644.5k
Susan Siegel	Independent Director	3.3yrs	US$243.00k	0.015% $ 68.7k
Shawn McCormick	Independent Director	9.6yrs	US$247.00k	0.055% $ 255.4k
Elizabeth Weatherman	Independent Director	5.1yrs	US$259.25k	0.13% $ 622.6k
D. Grossman	Non-Executive Chairman of the Board	5.1yrs	US$17.77m	0.52% $ 2.4m
Michael DeMane	Independent Lead Director	13.1yrs	US$285.00k	1.26% $ 5.9m
Kevin O'Boyle	Independent Director	5.1yrs	US$260.00k	0.048% $ 221.9k
Kirt Karros	Independent Director	less than a year	sin datos	sin datos
Karen Prange	Independent Director	4.3yrs	US$253.00k	0.022% $ 101.9k
Sridhar Kosaraju	Independent Director	2.5yrs	US$239.79k	0.030% $ 138.6k

5.1yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de NVRO se considera experimentada (4.8 años de antigüedad promedio).

Nevro Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Nevro Corp., Annual General Meeting, May 23, 2024

Independent Director recently bought US$172k worth of stock

Nevro Corp. Announces Executive Changes

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Nevro Corp. Announces Executive Changes

General Counsel recently bought US$100k worth of stock

Recent updates

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Price target decreased by 9.5% to US$19.40

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Full year 2023 earnings: EPS exceeds analyst expectations

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$26.37

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Consensus EPS estimates fall by 16%

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Price target decreased by 23% to US$28.80

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Price target decreased by 8.5% to US$37.57

Independent Director recently bought US$172k worth of stock

Price target decreased by 8.5% to US$38.43

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Nevro falls to 52-week low; down ~49% over last year

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Consensus forecasts updated

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Nevro: Opportunity Overshadowed By Weaknesses

Price target decreased to US$47.73

Consensus forecasts updated

Price target decreased to US$50.36

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Price target decreased to US$53.91

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro gets FDA approval for Costa Rica manufacturing operations

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro Corp. Announces Executive Changes

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations

Nevro Corp. Revises Earnings Guidance for the Full Year 2022

Nevro and Boston Scientific Corporation Announce the Settlement of Their Ongoing Intellectual Property Litigations

Nevro Corp. to Report Q2, 2022 Results on Aug 03, 2022

Nevro Corp. Announces the Complete 12-Month Results from the SENZA-PDN Randomized Controlled Trial

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery

Price target decreased to US$69.50

General Counsel recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Nevro Corp. Provides Earnings Guidance for the Second Quarter of 2022; Reiterates Earnings Guidance for the Year 2022

Nevro Corp., Annual General Meeting, May 26, 2022

Nevro Corp. to Report Q1, 2022 Results on May 04, 2022